Sarah has extensive international experience of financing early stage opportunities in the technology sector, with specific focus in life science and healthcare arena.
She has managed a large portfolio of academic programmes, charitable organisations, SMES and larger companies (public and private) to add value and achieve a commercial exit. Before joining the Archangels, Sarah worked in the Innovations Division of the Wellcome Trust, Advent Life Sciences venture team and Parke-Davis Neuroscience Research Centre. Sarah has a PhD in Molecular Neuropharmacology from the University of Aberdeen.
Sarah joined Archangels in March 2016 and has direct responsibility for number of the portfolio companies, particularly those focused on healthcare.